Sangamo Therapeutics

In News

Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan

Stock Titan - Dec 02, 2025

Why The Narrative Around Sangamo Therapeutics Is Shifting After Recent Analyst and FDA Updates - Yahoo Finance

Yahoo Finance - Nov 07, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy firm faces cash crunch amid promising pipeline - Investing.com

Investing.com - Sep 17, 2025

Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative

Quiver Quantitative - Nov 21, 2025

Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com

marketscreener.com - Dec 02, 2025

Sangamo's Fabry therapy partner search looks futile, and Geoff Porges is back - statnews.com

statnews.com - Sep 18, 2025

Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - Seeking Alpha

Seeking Alpha - Dec 02, 2025

With Sangamo Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis

Trefis - Nov 27, 2025

Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io

parameter.io - Dec 03, 2025

Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st

simplywall.st - Nov 23, 2025

Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growth - Breakout Watch & Real-Time Buy Signal Alerts - Newser

Newser - Dec 05, 2025

How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance

Yahoo Finance - Nov 27, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment